Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lee's Pharmaceutical Holdings's Revenue for the
six
months ended in Dec. 2025 was $95.3 Mil. Lee's Pharmaceutical Holdings's average Accounts Receivable for the
six
months ended in Dec. 2025 was $24.1 Mil.
Hence, Lee's Pharmaceutical Holdings's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.95.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lee's Pharmaceutical Holdings Receivables Turnover Related Terms
Lee's Pharmaceutical Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (LPCUF) has a Receivables Turnover of 3.95 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lee's Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #199 out of 951 companies in the Drug Manufacturers industry, placing it in the top 20.9%.
Is Lee's Pharmaceutical Holdings' Receivables Turnover too high?
Lee's Pharmaceutical Holdings' current Receivables Turnover is 3.95. The Drug Manufacturers industry median Receivables Turnover is 5.06. Lee's Pharmaceutical Holdings' value of 3.95 is 21.9% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #199 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #199 out of 951 companies for Receivables Turnover. This places Lee's Pharmaceutical Holdings in the top 21% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.06. Lee's Pharmaceutical Holdings' value of 3.95 is 21.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current Receivables Turnover of 3.95 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current Receivables Turnover is 3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current Receivables Turnover of 3.95. The stock's GF Value™ is $0.30, compared to a current price of $0.19 — trading 36.6% below its estimated fair value. The current Receivables Turnover is 3.95 and 21.9% below the Drug Manufacturers industry median of 5.06. Lee's Pharmaceutical Holdings' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current Receivables Turnover is 3.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of $0.19 is trading 36.6% below its estimated GF Value™ of $0.30.
Key valuation signals for LPCUF:
Receivables Turnover: 3.95
GF Value™: $0.30 vs. price of $0.19 (36.6% below fair value)
Industry Position: 21.9% below the Drug Manufacturers median (#199 of 951)
No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
73GF Score
Get the complete analysis for LPCUF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCUF has been successfully added to your 
